伊立替康联合亚甲蓝示踪进展期胃癌淋巴结的研究

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (7): 792-795.

伊立替康联合亚甲蓝示踪进展期胃癌淋巴结的研究

陈晓鹏¹, 王东¹, 王冠男¹, 胡明华¹, 张卫东¹, 张国政², 张帆³

¹皖南医学院弋矶山医院普外科,
²消化内科,
³病理科,芜湖 241001,安徽

收稿日期:2011-04-29 修回日期:2011-07-04 出版日期:2011-07-26 发布日期:2011-09-22
作者简介:陈晓鹏,男,博士,教授,主任医师,硕士生导师,研究方向:消化道肿瘤基础与临床研究。Tel: 0553-5739626 E-mail: drcxp@sohu.com
基金资助:
安徽省临床医学重点学科项目基金(05A016)

Study on lymph node tracing of advanced gastric cancer using irinotecan coupled with methylene blue

CHEN Xiao-peng¹, WANG Dong¹, WANG Guan-nan¹, HU Ming-hua¹, ZHANG Wei-dong¹, ZHANG Guo-zheng², ZHANG Fan³

¹Department of General Surgery,
²Department of Gastroenterology,
³Department of Pathology, Yijishan Hospital of Wannan Medical College, Wuhu 241001, Anhui, China

Received:2011-04-29 Revised:2011-07-04 Online:2011-07-26 Published:2011-09-22

摘要/Abstract

摘要： 目的: 探讨伊立替康联合亚甲蓝在进展期胃癌根治术中淋巴结示踪的效率及其机制。方法: 90例进展期胃癌随机分为非示踪组(31例)、亚甲蓝示踪组(30例)和伊立替康联合亚甲蓝示踪组(29例,简称联合示踪组),其中亚甲蓝示踪组术中用亚甲蓝 2 mL 分4点于瘤周浆膜下注射,联合示踪组用 40 mg 伊立替康与 2 mL 亚甲蓝耦合后分4点注射。3组均用多功能手术解剖器进行刮吸法胃癌根治淋巴结清扫。分别统计各组手术时间、出血量、输血量、清除淋巴结数和术后随访情况。结果: 非示踪组、亚甲蓝示踪组和联合示踪组平均手术时间分别为 (218±67)、(192±31)和(205±36 ) min(P＞0.05);平均出血量分别为(248±116)、(164±88)和(173±98) mL(P＜0.05),输血者平均输血量分别为(457±159)、(489±176)和(467±148) mL(P＞0.05);平均每例清除淋巴结数分别为(22±9)、(22±10)和(30±9)枚(P＜0.05),平均每例阳性淋巴结数分别为(7±3)、(6±3)和(9±3)枚(P＜0.05);3组分别有29、28和28例得到平均3年的随访,肿瘤复发率分别为 31.0%(9/29)、32.1%(9/28)和 21.4%(6/28) (P＞0.05),3年存活率分别为 62.1%(18/29)、57.1%(16/28)和 78.6%(22/28) (P＞0.05)。结论: 瘤周浆膜下注射伊立替康与亚甲蓝耦合液可明显提高进展期胃癌患者淋巴结清除效率,且安全简便。其机制可能是耦合液显著延长淋巴结染色和褪色时间,始终存在色觉导向刺激,激发术者进行准确而彻底的淋巴结清扫。

关键词: 胃癌, 淋巴结清扫术, 伊立替康, 亚甲蓝, 示踪剂

Abstract: AIM: To explore the effectiveness and mechanism of lymph node tracing using irinotecan coupled with methylene blue in radical resection of advanced gastric cancer.METHODS: 90 patients with advanced gastric cancer were randomly divided into the non-tracing group (n=31), methylene blue tracing group (n=30) and the combination tracing group (n=29). During operation, 2 mL of methylene blue was injected into the peritumoral subserosa at 4 points with microacupuncture needle in methylene blue tracing group, and the couplant of 40 mg of irinotecan and 2 mL methylene blue was injected in combination tracing group. The D₂/D₂⁺ lymphadenectomy was finished by curettage-aspiration dissection with Peng's multifunction operative dissector (PMOD) in all three groups. The operation time, intraoperative hemorrhage quantity, blood transfusion amount, the number of cleared lymph node and postoperative data of follow-up were collected.RESULTS: The average surgery time in three groups were (218±67),(192±31)and (205±36)min(P＞0.05), respectively. The intraoperative average hemorrhage quantity were(248±116),(164±88) and(173±98)mL(P＜0.05), and average blood transfusion amount of recipient's(457±159),(489±176)and (467±148) mL(P＞0.05), respectively. The average numbers of cleared lymph node were (22±9),(22±10) and(30±9)(P＜0.05) with positive lymph node(7±3),(6±3)and(9±3)(P＜0.05), respectively. By an average of 3 years of follow-up, the information of 29, 28 and 28 patients in three groups were collected respectively. The tumor recurrence rates were 31.0%(9/29), 32.1%(9/28) and 21.4%(6/28)(P＞0.05) in three groups while 3-year survival rates were 62.1%(18/29), 57.1%(16/28) and 78.6%(22/28) (P＞0.05), respectively.CONCLUSION: It is not only safe and convenient to inject the couplant of irinotecan and methylene blue into the peritumoral subserosa, but also significantly improve the effectiveness of lymphadenectomy in advanced gastric cancer. The possible mechanism is that the couplant obviously lengthens the dyeing and fading time of lymph nodes, gives color visual stimulation to the surgeon for exact and thorough lymph node dissection all the time during operation.

Key words: Gastric cancer, Lymphadenectomy, Irinotecan, Methylene blue, Tracer agents

中图分类号:

陈晓鹏, 王东, 王冠男, 胡明华, 张卫东, 张国政, 张帆. 伊立替康联合亚甲蓝示踪进展期胃癌淋巴结的研究[J]. 中国临床药理学与治疗学, 2011, 16(7): 792-795.

CHEN Xiao-peng, WANG Dong, WANG Guan-nan, HU Ming-hua, ZHANG Wei-dong, ZHANG Guo-zheng, ZHANG Fan. Study on lymph node tracing of advanced gastric cancer using irinotecan coupled with methylene blue[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 792-795.

参考文献

[1] 龚建平, 覃修福, 裘法祖. 胃癌根治术中间接淋巴显色剂的选择及其初步临床应用[J]. 中华实验外科杂志, 1992, 9(2): 90-91.
[2] 陈晓鹏, 童朝刚, 徐龙帅, 等. 伊立替康耦合亚甲蓝靶向示踪大鼠胃癌淋巴结的研究[J]. 中华实验外科杂志, 2010, 27(4): 126-127.
[3] 陈晓鹏, 李涛, 张国政, 等. 刮吸解剖法在进展期胃癌淋巴结清扫术中的应用[J]. 中国现代手术学杂志, 2007, 11(3): 168-170.
[4] 孙秀娣, 牧人, 周有尚, 等. 中国胃癌死亡率20年变化情况分析及其发展趋势预测[J]. 中华肿瘤杂志, 2004, 26 (1): 429.
[5] Baxter NN, Tuttle TM. Inadequacy of lymph node staging in gastric cancer patients: a population-based study [J]. Ann Surg Oncol, 2005, 12(12): 981-987.
[6] Saito H, Fukumoto Y, Osaki T, et al. Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach [J]. World J Surg, 2006, 30 (10): 1864-1869.
[7] Coleman LW, Bronstein IB, Holden JA. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas[J]. Anticancer Res, 2001, 21(2A): 1167-1172.
[8] Tsavaris N, Lazaris A, Kosmas C, et al. Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy[J]. Cancer Chemother Pharmacol, 2009, 64(2): 391-398.
[9] Moulder S, Valkov N, Neuger A, et al. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response[J]. Cancer, 2008, 113(10): 2646-2654.
[10] 方青芳. 化疗相关性腹泻的发生机制和治疗策略[J]. 中国临床药理学与治疗学, 2009, 14(3): 351-355.

[1]	王艳, 张金辉, 赵永辰, 刘宏祥, 刘亚维, 苗欢欢, 杨信才. 红杉黄酮通过下调PI3K/AKT信号通路抑制胃癌细胞增殖侵袭等干细胞特性[J]. 中国临床药理学与治疗学, 2023, 28(5): 508-513.
[2]	封壮壮, 宋瑞平, 豆鹏程, 陈心怡, 左娇娇, 舒劲. 基于mTOR/Beclin1/LC3信号轴探讨制萎扶胃丸对胃癌前病变大鼠胃窦组织自噬的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 361-370.
[3]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[4]	刘乐, 齐文博, 白玉萍, 刘乾, 尹振宇, 李晓梅, 俞阳, 陈昊. 胃癌PD-1/PD-L1免疫检查点抑制剂免疫治疗影响因素分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 95-101.
[5]	江玉华, 支慧, 卢林明, 田大皓, 王晓庆, 葛钰, 谢尚富, 王琪. 皖南蝮蛇毒抑瘤组分-I逆转原代胃癌相关成纤维细胞促癌作用[J]. 中国临床药理学与治疗学, 2021, 26(4): 389-394.
[6]	帕孜来提·亚森, 袁浩, 路红, 郑亚, 王玉平, 周永宁. 胃癌靶向治疗药物临床实验研究进展[J]. 中国临床药理学与治疗学, 2021, 26(4): 454-461.
[7]	吴懿, 朱阿考, 单毓强, 应荣超, 金慧成. 白藜芦醇调控miR-409-3p/FKBP14抑制胃癌细胞BGC823恶性进程[J]. 中国临床药理学与治疗学, 2020, 25(9): 968-975.
[8]	田大皓, 卢林明, 支慧, 周珏, 王晓庆, 江玉华. 皖南蝮蛇毒抑瘤组分-Ⅰ对人原代胃癌细胞增殖的影响[J]. 中国临床药理学与治疗学, 2020, 25(5): 505-511.
[9]	沈成，杨年钊，王明海，吴立胜，朱志强. RNA甲基化酶NSUN2对胃癌细胞侵袭和迁移的影响及机制研究[J]. 中国临床药理学与治疗学, 2020, 25(4): 380-386.
[10]	刘宇佳，李莉，胡晓平，钟里科，李晶晶，黄萍，张轶雯. 基于生物信息学的胃癌特征基因网络关键节点及预后关联分析[J]. 中国临床药理学与治疗学, 2019, 24(8): 852-859.
[11]	滕晓晶，董学妍，王智毅，余道军，王贤军. 扶正康复合剂联合顺铂抑制胃癌SGC7901细胞荷瘤裸鼠肿瘤增殖作用的实验研究[J]. 中国临床药理学与治疗学, 2019, 24(7): 744-749.
[12]	温纯洁，张颖，吴兰香，周宏灏. 维罗非尼对UGT1A1介导的伊立替康代谢的抑制作用研究[J]. 中国临床药理学与治疗学, 2019, 24(7): 773-777.
[13]	董金良. 每周脂质体紫杉醇联合替吉奥对老年晚期胃癌患者血清肿瘤标志物与可溶性E-钙黏连蛋白的影响[J]. 中国临床药理学与治疗学, 2019, 24(7): 805-809.
[14]	戴蕾，罗灵和，吴黎艳，王刚，费保莹. miR-222、MBD2在胃癌患者中的表达及对铂类化疗敏感性的影响[J]. 中国临床药理学与治疗学, 2019, 24(6): 623-629.
[15]	张腾跃，杨广山，马克龙，范平生. 抗凝治疗对中晚期胃癌改善高凝状态、抗肿瘤转移的临床研究[J]. 中国临床药理学与治疗学, 2019, 24(4): 433-439.